Compare Air Products & Chemicals, Inc. (APD) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Air Products & Chemicals, Inc. vs Citius Pharmaceuticals Inc — how do they compare? Air Products & Chemicals, Inc. trades at $300.37 (market cap $66.70B), while Citius Pharmaceuticals Inc trades at $0.58 (market cap $16.00M). The key difference: Air Products & Chemicals, Inc. is far larger — about 4168.8× Citius Pharmaceuticals Inc's market cap, and Air Products & Chemicals, Inc. pays a 2.42% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| APD | CTXR | |
|---|---|---|
Market Cap | $66.70B | $16.00M |
Sector | Basic Materials | Health |
52-Week High | $314.19 | $1.82 |
52-Week Low | $230.42 | $0.53 |
Enterprise Value | $84.11B | $12.21M |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APD trades at $299.53, up 1.24% today, with a bullish technical signal from moving averages and strong analyst support. Recent earnings beats and strategic project exits, like the Louisiana Clean Energy Complex, have boosted investor confidence. The company maintains solid profitability margins but faces pressure from a negative net income in 2025 due to a pre-tax charge. Cash flow trends show volatility, with significant investing outflows for growth initiatives.
The outlook is positive with a consensus price target of $324.89, implying ~8% upside. Risks include high debt levels, execution on new projects, and macroeconomic sensitivity. Long-term growth is supported by renewable energy investments, but near-term profitability recovery is key for sustained gains.
CTXR trades at $0.5827, up 3.81% today, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported a net loss of $37.43M in 2025 with a -823.34% net margin, though revenue reached $5.6M in H1 2026 from LYMPHIR commercialization. Recent news highlights positive Phase 1 data for LYMPHIR presented at ASCO 2026.
Outlook remains speculative with high cash burn offset by financing; analyst consensus is 83% buy but financial sustainability depends on successful drug adoption. Key risks include clinical trial outcomes, dilution from recent $5M offering, and achieving profitability amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Air Products & Chemicals, Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Read more on APD →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
